Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012;9(7):e1001273.
doi: 10.1371/journal.pmed.1001273. Epub 2012 Jul 24.

Treatment of young children with HIV infection: using evidence to inform policymakers

Andrew J Prendergast  1 , Martina Penazzato, Mark Cotton, Philippa Musoke, Veronica Mulenga, Elaine J Abrams, Diana M Gibb
Affiliations
Review

Treatment of young children with HIV infection: using evidence to inform policymakers

Andrew J Prendergast et al. PLoS Med. 2012.

Abstract

Andrew Prendergast and colleagues consider the evidence for a change in policy for the treatment of young children infected with HIV.

PubMed Disclaimer

Conflict of interest statement

AP is a co-investigator on the PEHSS and ARROW trials but did not receive any funds for participation in these trials. MP has been supported by the European Union (EU; FP7) through the Paediatric European Network for the Treatment of AIDS Foundation for the past three years and is currently working as a consultant for the HIV Department at the World Health Organization (WHO). MC was a co-investigator on the P1060 and CHER trials and funds for the P1060 trial contributed to MC's salary. MC is an investigator for the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) group, funded through the Division of AIDS (DAIDS), National Institute of Allergy & Infectious Diseases (NIAID). MC has been an investigator for pharmaceutical trials for BMS and GSK from 2008 to present; funds provide site support but no contribution to his salary. MC is a member of Essential Drug list committee for children in public hospitals (2008–2012) and the Paediatric Expert Group for National Department of Health and HIV Clinicians Society of Southern Africa. MC is a member of the WHO technical task team for paediatric ARV guidelines; attended meetings from 2006 to 2008; and still contributes opinions by email. PM is a co-investigator on the ARROW trial and receives funding from DAIDS and MRC UK for this work. VM is an investigator on the CHAPAS 3 trial and receives a project management allowance for her work. VM is a member of the WHO Paediatric Antiretroviral Working Group (PAWG) committee; travel to a PAWG meeting was paid for by WHO in October 2011. EJA is a co-investigator on the P1060 and NEVEREST trials and funds from the NEVEREST trial contribute to EJA's salary. EJA is an investigator for the IMPAACT group, funded through DAIDS, NIAID. EJA is Chair of the HIV Treatment Committee, IMPAACT group. EJA receives partial salary support from NIAID for her role as Chair and medications for studies are generally donated. EJA is a member of the US Public Health Service (USPHS) guidelines committee for antiretroviral treatment of children and co-Chair of the WHO Antiretroviral Guidelines Committee. She receives no financial support for these activities. DMG is a co-investigator on the ARROW trial and receives funding from the MRC UK, DFID, EDCTP, and EU (FP7). DMG has been Chair of Data Monitoring Committees for industry paediatric trials undertaken by Tibotec (now finished). AP, MP, EJA, and DMG are members of the WHO paediatric ARV working group but receive no financial support for this activity.

References

    1. World Health Organization, UNAIDS. Global HIV/AIDS response: progress report 2011. 2011. Available: http://www.unaids.org/en/resources/publications/2011/. Accessed 18 March 2012.
    1. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364:1236–1243. - PubMed
    1. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010;304:1082–1090. - PMC - PubMed
    1. Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Epub ahead of print 15 March 2012. - PMC - PubMed
    1. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Eng J Med. 2010;363:1510–1520. - PMC - PubMed